Drawing for ARAS

USPTO serial 86050419

ARAS

Reviewed by CopyMark Law Group

Reg. 4689448Status 710
Filing date
Status date
Registration date
Feb 17, 2015
Examiner
GALAN, MATTHEW
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with ARAS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Steven M. Rabin

STEVEN M. RABIN RABIN & BERDO, P.C.1101 14TH ST NW STE 500WASHINGTON, DC 20005-5633UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Adjuvants for medical purposes; Antiallergic medicines; Anti-cancer preparations; Medicinal herbal extracts for medical purposes; Pharmaceutical and medicinal preparations and substances for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, ocular disorders, or bone diseases, for use in dermatology, oncology, hematology and ophthalmology and for gastroenterological disorders or liver ailments; Pharmaceutical and medicinal preparations for the treatment of brain diseases or disorders and autoimmune diseases or disorders; Dietary and nutritional supplements for medical use; Dietary supplements for treating fatigue or liver support; Animal feed additive for use as a nutritional supplement for medical purposes; Dietary supplements for human consumption or for animals; Nutritional additives for medical purposes for use in foods for human consumption or for animals; Animal feed supplements; Dietary pet supplements in the form of pet treats; Fungi preparations for medical or veterinary use for treating disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, ocular disorders, brain diseases or disorders, autoimmune diseases or disorders, or bone diseases, for use in dermatology, oncology, hematology and ophthalmology and for gastroenterological disorders or liver ailments; Pharmaceutical preparations and substances for veterinary purposes for treating disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, ocular disorders, brain diseases or disorders, autoimmune diseases or disorders, or bone diseases, for use in dermatology, oncology, hematology and ophthalmology and for gastroenterological disorders or liver ailments; Chemical preparations for medicinal purposes for treating disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, ocular disorders, brain diseases or disorders, autoimmune diseases or disorders, or bone diseases, for use in dermatology, oncology, hematology and ophthalmology and for gastroenterological disorders or liver ailments; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Pharmaceuticals preparations for the treatment of kidney diseasesSECTION 8 - CANCELLEDAug 19, 2014

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 24, 2021C8..CANCELLED SEC. 8 (6-YR)—
Feb 17, 2020REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Feb 17, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 15, 2015SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jan 14, 2015CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jan 14, 2015SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jan 13, 2015AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 5, 2014IUAFUSE AMENDMENT FILED—
Dec 5, 2014EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Oct 14, 2014NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 19, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 19, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 30, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 12, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 3, 2014ALIEASSIGNED TO LIE—
Jun 17, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 30, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 30, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 30, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 16, 2013GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 16, 2013GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 16, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 11, 2013DOCKASSIGNED TO EXAMINER—
Sep 6, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 31, 2013NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance